Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.58 |
| ▸ | CNR1 | P21554 | 3/20 | 0.52 |
| ▸ | MAOB | P27338 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | SQOR | Q9Y6N5 | 1/20 | 0.48 |
| ▸ | XDH | P47989 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | ATP4A | P20648 | 1/20 | 0.42 |
| ▸ | ATP4B | P51164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15831934 | 0.88 | HDAC1 (0.56) | HDAC1CNR1L3MBTL1XDHGAA | |
| SCHEMBL15831936 | 0.87 | HDAC1 (0.52) | HDAC1CNR1XDH | |
| SCHEMBL15831942 | 0.87 | HDAC1 (0.55) | HDAC1CNR1MAOBL3MBTL1TSHR | |
| SCHEMBL15831935 | 0.85 | HDAC1 (0.54) | HDAC1CNR1XDH | |
| SCHEMBL15831946 | 0.85 | HDAC1 (0.54) | HDAC1CNR1XDH | |
| SCHEMBL15831937 | 0.85 | HDAC1 (0.48) | HDAC1CNR1MAOBL3MBTL1GAA | |
| SCHEMBL15831940 | 0.85 | HDAC1 (0.48) | HDAC1SQORTSHR | |
| SCHEMBL15831943 | 0.83 | HDAC1 (0.54) | HDAC1CNR1XDH | |
| SCHEMBL15831933 | 0.83 | MPO (0.48) | HDAC1CNR1MAOB | |
| SCHEMBL15831945 | 0.82 | HDAC1 (0.51) | HDAC1CNR1MAOBL3MBTL1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140179686-A1 | Novel Vanilloid Receptor Ligands and Use Thereof for the Production of Pharmaceutical Preparations | GRUENENTHAL GMBH (DE) | 2014-06-26 | — | — | US | disclosed |
| US-20090137499-A1 | BENZYLPHENYL GLUCOPYRANOSIDE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-05-28 | — | — | US | disclosed |
| EP-2048150-A1 | BENZYL PHENYL GLUCOPYRANOSIDE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2009-04-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137499-A1 | BENZYLPHENYL GLUCOPYRANOSIDE DERIVATIVE | SLC5A1, SLC5A2, SLC2A1 | HDAC1 289/4885CNR1 661/4885MAOB 3258/4885 |
| US-20140179686-A1 | Novel Vanilloid Receptor Ligands and Use Thereof for the Production of Pharmaceutical Preparations | TRPV1, TRPV5, TRPV2 | HDAC1 4587/4885CNR1 19/4885MAOB 2509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.